Cytotoxicity of HA22 and HA22-LR toward freshly obtained CLL and HCL cells
| . | IC50 ± SD (ng/mL) . | Relative activity . | Assay type . | |
|---|---|---|---|---|
| HA22 . | HA22-LR . | |||
| CLL 1 | > 1000 | 4.7 ± 0.54 | > 210 | Protein synthesis |
| CLL 1 | 55 ± 12.8 | 3.4 ± 0.53 | 16.2 | Cell death |
| CLL 2 | 16.8 ± 1.05 | < 1 | > 16.8 | Protein synthesis |
| CLL 2 | 10.1 ± 0.48 | 1.32 ± 0.164 | 7.65 | Cell death |
| CLL 3 | 8.1 ± 2.1 | 3.9 ± 0.50 | 2.07 | Protein synthesis |
| CLL 4 | 290 ± 167 | 5.6 ± 1.10 | 51.8 | Protein synthesis |
| CLL 5 | 8.0 ± 1.51 | 3.7 ± 0.27 | 2.16 | Protein synthesis |
| HCL 1 | 5.2 ± 0.37 | 5.9 ± 1.03 | 0.88 | Protein synthesis |
| HCL 2 | 0.177 ± 0.0062 | 1.25 ± 0.24 | 0.14 | Protein synthesis |
| HCL 2 | 0.165 ± 0.0098 | 2.0 ± 0.39 | 0.08 | Cell death |
| HCL 3 | 1.76 ± 0.51 | < 1 | > 1.76 | Protein synthesis |
| HCL 3 | 2.1 ± 0.51 | 1.51 ± 0.29 | 1.39 | Cell death |
| . | IC50 ± SD (ng/mL) . | Relative activity . | Assay type . | |
|---|---|---|---|---|
| HA22 . | HA22-LR . | |||
| CLL 1 | > 1000 | 4.7 ± 0.54 | > 210 | Protein synthesis |
| CLL 1 | 55 ± 12.8 | 3.4 ± 0.53 | 16.2 | Cell death |
| CLL 2 | 16.8 ± 1.05 | < 1 | > 16.8 | Protein synthesis |
| CLL 2 | 10.1 ± 0.48 | 1.32 ± 0.164 | 7.65 | Cell death |
| CLL 3 | 8.1 ± 2.1 | 3.9 ± 0.50 | 2.07 | Protein synthesis |
| CLL 4 | 290 ± 167 | 5.6 ± 1.10 | 51.8 | Protein synthesis |
| CLL 5 | 8.0 ± 1.51 | 3.7 ± 0.27 | 2.16 | Protein synthesis |
| HCL 1 | 5.2 ± 0.37 | 5.9 ± 1.03 | 0.88 | Protein synthesis |
| HCL 2 | 0.177 ± 0.0062 | 1.25 ± 0.24 | 0.14 | Protein synthesis |
| HCL 2 | 0.165 ± 0.0098 | 2.0 ± 0.39 | 0.08 | Cell death |
| HCL 3 | 1.76 ± 0.51 | < 1 | > 1.76 | Protein synthesis |
| HCL 3 | 2.1 ± 0.51 | 1.51 ± 0.29 | 1.39 | Cell death |